---
schema_version: "secwatch.filing_event.v1"
accession: "0001559053-24-000034"
form_type: "8-K"
ticker: "PRTA"
cik: "0001559053"
company_name: "PROTHENA CORP PUBLIC LTD CO"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:52:32.886472+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Prothena reports Q3 net loss of $59M on $1M revenue, cash at $520M; pipeline readouts expected in 2024-2025

## Summary
- Net loss of $59.0M ($1.10 per share) vs net income of $21.9M ($0.38 diluted) in Q3 2023; revenue fell to $1.0M from $84.9M.
- Cash and restricted cash $520.1M as of Sep 30 2024; full-year net cash use guidance reaffirmed at $148-$160M.
- Expects topline results from Phase 2b PADOVA (prasinezumab) in 4Q2024 and Phase 3 AFFIRM-AL (birtamimab) in 1H2025.
- Phase 1 ASCENT trials (PRX012) for Alzheimer's disease to report multiple readouts starting mid-2025.
- Appointed Chad J. Swanson, Ph.D., as Chief Development Officer in September 2024.

## SEC filing metadata
- accession: 0001559053-24-000034
- form_type: 8-K
- ticker: PRTA
- cik: 0001559053
- company_name: PROTHENA CORP PUBLIC LTD CO
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1559053/000155905324000034/0001559053-24-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1559053/000155905324000034/prta-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001559053-24-000034
- JSON: https://secwatch.observer/filing/0001559053-24-000034.json
- Plain text: https://secwatch.observer/filing/0001559053-24-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.